These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 11837705)
1. Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. Haidar SH; Johnson SB; Fossler MJ; Hussain AS Pharm Res; 2002 Jan; 19(1):87-91. PubMed ID: 11837705 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Hatorp V Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269 [TBL] [Abstract][Full Text] [Related]
4. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106 [TBL] [Abstract][Full Text] [Related]
5. Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function. Goud T; Maddi S; Nayakanti D; Thatipamula RP Drug Metab Pers Ther; 2016 Jun; 31(2):123-30. PubMed ID: 27166727 [TBL] [Abstract][Full Text] [Related]
6. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Niemi M; Neuvonen PJ; Kivistö KT Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245 [TBL] [Abstract][Full Text] [Related]
7. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. Hatorp V; Hansen KT; Thomsen MS J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528 [TBL] [Abstract][Full Text] [Related]
8. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883 [TBL] [Abstract][Full Text] [Related]
10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Niemi M; Backman JT; Neuvonen M; Neuvonen PJ Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332 [TBL] [Abstract][Full Text] [Related]
11. Rifampin decreases the plasma concentrations and effects of repaglinide. Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752 [TBL] [Abstract][Full Text] [Related]
12. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. Rawat MK; Jain A; Singh S J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451 [TBL] [Abstract][Full Text] [Related]
13. Cyclosporine markedly raises the plasma concentrations of repaglinide. Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658 [TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822 [TBL] [Abstract][Full Text] [Related]
15. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Scheen AJ Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883 [TBL] [Abstract][Full Text] [Related]
16. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304 [TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447 [TBL] [Abstract][Full Text] [Related]
18. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. Hatorp V; Huang WC; Strange P J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798 [TBL] [Abstract][Full Text] [Related]
20. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]